Centralised Pan-European Survey on the Undertreatment of Hyperchlesterolemia - CEPHEUS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-000954-31-FI

Enrollment

20900

Registered

2006-03-23

Start date

2006-05-05

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients on lipid-lowering pharmacological treatment

Interventions

Pharmaceutical Form:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Subject must be 18 years of age or older of either sex and of any race. -Subject must demonstrate his/her willingness to participate in the survey and comply with its procedures by signing a written informed consent. -Subject is on lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: -Subjects who are unwilling or unable to provide informed consent.

Design outcomes

Primary

Measure	Time frame
Main Objective: To establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines, overall and by country.;Secondary Objective: -establish proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines in the primary/secondary prevention patients and patients with metabolic syndrome -establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III/national guidelines, in the survey population and in the primary/secondary prevention patients and patients with metabolic syndrome. -identify determinants for undertreatment of hypercholesterolemia. Undertreatment is defined as receiving lipid-lowering pharmacological treatment and not reaching the LDL-C goals according to the Third Joint European Task Force/NCEP ATP III/updated 2004 NCEP ATP III guidelines. -To explore physician characteristics associated with the allocation of treatment regime.;Primary end point(s): The number and percentage of subjects achieving the LDL-C goals, according to the Third Joint European Task Force guidelines, overall and by country.	—

Measure

Time frame

Main Objective: To establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines, overall and by country.;Secondary Objective: -establish proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines in the primary/secondary prevention patients and patients with metabolic syndrome -establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III/national guidelines, in the survey population and in the primary/secondary prevention patients and patients with metabolic syndrome. -identify determinants for undertreatment of hypercholesterolemia. Undertreatment is defined as receiving lipid-lowering pharmacological treatment and not reaching the LDL-C goals according to the Third Joint European Task Force/NCEP ATP III/updated 2004 NCEP ATP III guidelines. -To explore physician characteristics associated with the allocation of treatment regime.;Primary end point(s): The number and percentage of subjects achieving the LDL-C goals, according to the Third Joint European Task Force guidelines, overall and by country.

—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026